Skip to main content

CASE REPORT article

Front. Med.

Sec. Pathology

Volume 12 - 2025 | doi: 10.3389/fmed.2025.1526614

Gastric submucosal neoplasm with CTNNB1 mutation showing GLI1 overexpression and epithelial differentiation

Provisionally accepted
Karin Ashizawa Karin Ashizawa 1Tsuyoshi Saito Tsuyoshi Saito 1*Yukinori Yube Yukinori Yube 2Shinji Mine Shinji Mine 2Tetsu Fukunaga Tetsu Fukunaga 2Cristina R Antonescu Cristina R Antonescu 3Takashi Yao Takashi Yao 1
  • 1 Human Pathology, Juntendo University, Bunkyō, Japan
  • 2 Upper Gastroenterological Surgery, Juntendo University, Bunkyō, Japan
  • 3 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, United States

The final, formatted version of the article will be published soon.

    New disease entities have been emerging based on molecular pathological findings, such as pseudoendocrine sarcoma and mesenchymal neoplasm with GLI1 gene alterations, which resemble well-differentiated neuroendocrine tumors. We report a unique case of a gastric submucosal neoplasm of approximately 1.5cm in size with CTNNB1 mutation showing GLI1 overexpression and epithelial differentiation in a 66-year-old man. It was incidentally identified by routine health screening, and was a slowly growing tumor. Macroscopically, it was a slightly protruded tumor into the mucosa, and was primarily located from the submucosa to the muscularis propria. It was a well-defined lesion measured approximately 20mm, and was almost stable during almost 5 years after initial identification of the tumor. Uniform round-to-epithelioid cells arranged in solid trabeculae with a microtubular/acinar appearance were seen microscopically. Occasional mitotic figures were noted, but no necrosis was observed. Immunohistochemistry (IHC) demonstrated diffuse expression of pan-cytokeratin, CD10, and CD56 without neuroendocrine markers (chromogranin A, synaptophysin, and INSM1). Molecular analysis confirmed the presence of a hot spot CTNNB1 mutation (S33C), supported by diffuse βcatenin nuclear expression by IHC. Further molecular investigations revealed the absence of GLI1 gene rearrangements, GLI1 amplification, and other fusions. Several differential diagnoses were considered; however, none adequately fit the criteria. The patient remained disease-free for 24 months postoperatively without further adjuvant therapy.

    Keywords: pseudoendocrine sarcoma, Stomach, CTNNB1, cytokeratin, Epithelial, neuroendocrine, GLI1

    Received: 12 Nov 2024; Accepted: 03 Mar 2025.

    Copyright: © 2025 Ashizawa, Saito, Yube, Mine, Fukunaga, Antonescu and Yao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Tsuyoshi Saito, Human Pathology, Juntendo University, Bunkyō, Japan, Japan

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    94% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more